Regeneron Pharmaceuticals REGN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's investing cash flow?
- Regeneron Pharmaceuticals (REGN) reported investing cash flow of -$428.9M in Q1 2026.
- How has Regeneron Pharmaceuticals's investing cash flow changed year-over-year?
- Regeneron Pharmaceuticals's investing cash flow decreased by 166.2% year-over-year, from $647.5M to -$428.9M.
- What is the long-term trend for Regeneron Pharmaceuticals's investing cash flow?
- Over 2 years (2021 to 2023), Regeneron Pharmaceuticals's investing cash flow has grown at a -24.0% compound annual growth rate (CAGR), from -$5.51B to -$3.19B.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.